AMAG – AMAG Pharmaceuticals, Inc. – Safety concerns surrounding AMAG’s Feraheme, the biopharmaceutical firm’s intravenous iron-replacement therapy for patients with chronic kidney disease and its lead product, continue to drive shares to new lows. Shares are down 4.00% at $18.15 as of 3:20 pm ET, but earlier plunged 11.6% to touch down at an intraday- and 4-year low of $16.70. Today’s low of $16.70 put shares down 68.2% since January 12, 2010, when the stock was trading up at its 52-week high of $52.49. Erosion in the price of AMAG’s shares accelerated at the end of August when the FDA added Feraheme to a list of products touting serious risks and connected the drug to unspecified serious cardiac disorders. One options investor appears to be positioning for shares to continue to decline by enacting a ratio put spread in the October contract. The trader purchased approximately 2,500 puts at the October $18 strike for premium of $1.98 each, and sold roughly 5,000 puts at the lower October $16 strike at a premium of $0.84 apiece. Average net premium paid to establish the spread amounts to $0.30 per contract. Thus, the strategist stands ready to profit if AMAG’s shares slip beneath the effective breakeven price of $17.70 by expiration. Maximum potential profits of $1.70 per contract are available to the trader if AMAG shares fall 11.85% from the current price of $18.15 to settle at $16.00 at expiration. The ratio of twice as much sold puts as long puts held by the investor expose him to losses should shares collapse below the effective lower breakeven price of $14.30 by expiration day next month.
Affiliation: Interactive Brokers
Andrew Wilkinson is the senior market analyst at Interactive Brokers Group, where he provides daily commentary and analysis on U.S. equity options trading throughout the trading day. Andrew provides webinars designed to explain option-related trading scenarios covering futures, fixed income, forex and equities.
Interactive Brokers: Interactive Brokers offers direct market access to around 80 electronic global markets from a single account. Successful traders and investors understand that superior technology and lower trading costs can result in greater returns. For 32 years we have been building direct access trading technology that delivers real advantages to professionals worldwide. With consolidated equity capital of US $4.4 billion, IB and its affiliates exceed 1,000,000 trades per day. In addition, our prudent and conservative risk policies make Interactive Brokers a safe haven for your money. Discover some of the reasons why IB, the largest independent US broker/dealer, is the professional traders' and investors' choice.
Visit: Interactive Brokers